$21.68
+0.43 (+2.02%)
Open$21.21
Previous Close$21.25
Day High$21.69
Day Low$21.00
52W High$37.50
52W Low$18.19
Volume—
Avg Volume38.6K
Market Cap85.76M
P/E Ratio—
EPS$-21.82
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+25.8% upside
Current
$21.68
$21.68
Target
$27.28
$27.28
$18.57
$27.28 avg
$35.01
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 34.52M | 12.22M | 12.16M |
| Net Income | -89,026,856 | 1.67M | 1.59M |
| Profit Margin | -257.9% | 13.7% | 13.1% |
| EBITDA | -64,036,156 | 2.79M | 3.00M |
| Free Cash Flow | — | 1.30M | 1.27M |
| Rev Growth | — | +12.4% | +20.7% |
| Debt/Equity | 0.81 | 0.63 | 0.63 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.35 | -1.10% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $419.87 | +0.42% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.65 | -1.02% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $525.69 | -0.38% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | +0.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $252.46 | -1.14% | 41.4 | 33.44B |